ADC Therapeutics Net Income vs. Return On Asset

ADCT Stock  USD 2.03  0.04  2.01%   
Based on ADC Therapeutics' profitability indicators, ADC Therapeutics' profitability may be sliding down. It has an above-average probability of reporting lower numbers next quarter. Profitability indicators assess ADC Therapeutics' ability to earn profits and add value for shareholders.
 
Net Loss  
First Reported
2018-03-31
Previous Quarter
-36.5 M
Current Value
-44 M
Quarterly Volatility
27.8 M
 
Covid
At this time, ADC Therapeutics' Days Sales Outstanding is comparatively stable compared to the past year. Days Of Sales Outstanding is likely to gain to 227.88 in 2024, whereas Price To Sales Ratio is likely to drop 1.85 in 2024. At this time, ADC Therapeutics' Income Tax Expense is comparatively stable compared to the past year. Change To Netincome is likely to gain to about 60 M in 2024, whereas Interest Income is likely to drop slightly above 5 M in 2024.
For ADC Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ADC Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ADC Therapeutics SA utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ADC Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ADC Therapeutics SA over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Is Communications Equipment space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADC Therapeutics. If investors know ADC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ADC Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.39)
Revenue Per Share
0.774
Quarterly Revenue Growth
0.274
Return On Assets
(0.21)
Return On Equity
(7.06)
The market value of ADC Therapeutics is measured differently than its book value, which is the value of ADC that is recorded on the company's balance sheet. Investors also form their own opinion of ADC Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is ADC Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ADC Therapeutics' market value can be influenced by many factors that don't directly affect ADC Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ADC Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ADC Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ADC Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

ADC Therapeutics Return On Asset vs. Net Income Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining ADC Therapeutics's current stock value. Our valuation model uses many indicators to compare ADC Therapeutics value to that of its competitors to determine the firm's financial worth.
ADC Therapeutics SA is number one stock in net income category among its peers. It also is number one stock in return on asset category among its peers . At this time, ADC Therapeutics' Net Loss is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value ADC Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

ADC Return On Asset vs. Net Income

Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

ADC Therapeutics

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

 = 
(240.05 M)
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

ADC Therapeutics

Return On Asset

 = 

Net Income

Total Assets

 = 
-0.21
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.

ADC Return On Asset Comparison

ADC Therapeutics is currently under evaluation in return on asset category among its peers.

ADC Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in ADC Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, ADC Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of ADC Therapeutics' change in net profit over the period of time. It can combine multiple indicators of ADC Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-93 K-88.3 K
Net Interest Income-39.6 M-37.6 M
Interest Income6.6 MM
Operating Income-166 M-174.3 M
Net Loss-178.5 M-187.4 M
Income Before Tax-195.4 M-205.2 M
Total Other Income Expense Net-29.4 M-28 M
Net Loss-140.2 M-147.2 M
Net Loss-240.1 M-252.1 M
Income Tax Expense39.1 M41.1 M
Change To Netincome57.1 M60 M
Net Loss(2.94)(3.08)
Income Quality 0.49  0.94 
Net Income Per E B T 1.23  0.82 

ADC Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on ADC Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of ADC Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the ADC Therapeutics' important profitability drivers and their relationship over time.

Use ADC Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ADC Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ADC Therapeutics will appreciate offsetting losses from the drop in the long position's value.

ADC Therapeutics Pair Trading

ADC Therapeutics SA Pair Trading Analysis

The ability to find closely correlated positions to ADC Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ADC Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ADC Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ADC Therapeutics SA to buy it.
The correlation of ADC Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ADC Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ADC Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ADC Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your ADC Therapeutics position

In addition to having ADC Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Airlines Thematic Idea Now

Airlines
Airlines Theme
Domestic and international airlines and airline services. The Airlines theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Airlines Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for ADC Stock Analysis

When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.